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a  b  s  t  r  a  c  t
Siglec-8  and  siglec-F  are  paralogous  membrane  proteins  expressed  on  human  and  murine  eosinophils
respectively.  They  bind  similar  sialylated  and  sulphated  glycans  and  mediate  eosinophil  apoptosis  when
cross-linked  with  antibodies  or glycan  ligands.  In models  of allergic  eosinophilic  airway  inﬂammation,
siglec-F  was  shown  previously  to be important  for negatively  regulating  eosinophilia.  It was  proposed
that  this  was  due  to siglec-F-dependent  apoptosis,  triggered  via engagement  with  ligands  that  are  upre-
gulated  on bronchial  epithelium.  Our  aim  was  to further  investigate  the  functions  of  siglec-F  by comparing
two  commonly  used  models  of ovalbumin-induced  airway  inﬂammation  that  differ  in  the  dose  and
route  of  administration  of ovalbumin.  In conﬁrmation  of  published  results,  siglec-F-deﬁcient  mice  had
enhanced  lung  tissue  eosinophilia  in  response  to  intranasal  ovalbumin  delivered  every  other  day.  How-
ever,  following  aerosolised  ovalbumin  delivered  daily,  there  was  no  inﬂuence  of  siglec-F deﬁciency  on
lung  eosinophilia.  Expression  of  siglec-F  ligands  in  lung  tissues  was  similar  in  both  models  of  allergen
induced  inﬂammation.  These  data  demonstrate  that  siglec-F-dependent  regulation  of eosinophilia  is
subtle  and  depends  critically  on the  model  used.  The  ﬁndings  also  indicate  that  mechanisms  other  than
ligand-induced  apoptosis  may  be  important  in siglec-F-dependent  suppression  of eosinophilia.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Siglecs-8 and -F are paralogous membrane proteins highly
expressed on human and mouse eosinophils respectively. They
are members of the CD33-related sialic acid binding Ig-like
lectin (siglec) family and contain immunoreceptor tyrosine based
inhibitory motifs (ITIM) and ITIM-like motifs in their cytoplas-
mic  tails that are implicated in negative regulatory functions
[1]. Previous studies have shown that cross-linking of siglecs-8
and -F in vitro using speciﬁc antibodies or glycan ligands can
lead to eosinophil apoptosis [2,3]. This has raised the possibility
that selective targeting of these cells in diseases such as allergic
asthma could be beneﬁcial [2–5]. Although murine siglec-F is not
orthologous with siglec-8, their similarities in expression pattern
[6,7], proapoptotic properties [4,8], and ligand binding preference
[6] suggest that these proteins play equivalent functional roles.
Abbreviations: Siglec, sialic acid binding immunoglobulin like lectin; OVA, oval-
bumin; WT,  wild type; KO, knock out; KI, knock in; ITIM, immunoreceptor tyrosine
based inhibitory motifs.
∗ Corresponding author. Tel.: +44 1382 385781.
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Therefore, analysis of siglec-F-deﬁcient mice is likely to give
insights into siglec-8 functions in humans.
Siglec-F has been shown to act as a negative regulator of
ovalbumin (OVA)-induced eosinophilia since OVA-primed and
challenged siglec-F-deﬁcient mice had enhanced eosinophilic air-
way inﬂammation and increased numbers of eosinophils in the
blood and bone marrow [9,10]. Moreover, siglec-F antibodies were
shown to reduce eosinophilic inﬂammation in a model of OVA-
induced airway inﬂammation [11]. Siglec-F ligands are expressed
on bronchial epithelium and inﬂammatory leukocytes, including
eosinophils themselves [9,10,12]. Two  recent studies demonstrated
that the sialyltransferase ST3Gal-III is required for siglec-F ligand
expression and that ST3Gal-III-deﬁcient mice exhibited increased
lung eosinophilia in a model of OVA-induced allergic lung inﬂam-
mation [13,14]. Collectively, these data have given rise to the
hypothesis that engagement of siglec-8 or siglec-F with sialylated
ligands leads to eosinophil apoptosis and negative regulation of
eosinophil inﬂammation in the lung.
The above studies on siglec-F-dependent modulation of
eosinophilia have been performed using a model of OVA-induced
airway inﬂammation in which OVA-primed mice are challenged
intranasally with OVA. Since it has been well documented that use
of different murine models of allergic airway disease can result in
contrasting data [15,16], we sought to compare the development
http://dx.doi.org/10.1016/j.imlet.2014.03.008
0165-2478/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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of OVA-induced airway eosinophilia using two different models
with previously unreported siglec-F-deﬁcient mice generated in
our laboratory.
Here we demonstrate that, in contrast to intranasal OVA deliv-
ery every other day, when aerosolised OVA was delivered daily,
the absence of siglec-F did not lead to increased numbers of lung
eosinophils. These differences in siglec-F-dependent eosinophil
recruitment could not be explained by altered siglec-F ligand
expression in the lung which was similar in both models. Our ﬁnd-
ings suggest that the negative regulatory effects of siglec-F may  be
overridden under certain inﬂammatory conditions and have impor-
tant implications for the translation of siglec-F in mouse models of
allergic inﬂammation to human siglec-8 in asthma.
2. Materials and methods
2.1. Generation and characterization of siglec-F-deﬁcient mice
Siglec-FR114D ‘knock in’ (KI) mice, carrying an Arg114 to Asp
mutation in the siglec-F gene predicted to abolish sialic acid bind-
ing [10], were generated by Taconic Artemis using C57BL/6 ES
cells and the targeting strategy illustrated in Fig. 1A. Further cross-
ing of homozygous siglec-FR114D mice with Tg (Nes-cre)1Wme/J
(Bal1 cre) mice produced offspring with mosaicism/partial dele-
tion of exons 6–9 in adult organs (including germline), resulting
in the truncated siglec-F ‘knock out’ (KO) allele shown in
Fig. 1A. Mosaic offspring were then used to generate siglec-F−/−
mice, which was conﬁrmed by PCR. The following primers gave
rise to a wild-type product (202 bp), a KI product (321 bp) or
a KO product (363 bp); 1928 35; CCTGATGTCATGTGTGAAGTCG,
1928 36; GATTTCAGGCGTGTGATTGC, 1928 38; CTCCTGAGGGCT-
GAGACTATAGG. WT,  siglec-FR114D and siglec-F−/− mice were
generated using parents from heterozygous intercrosses on
C57BL/6 background. Mice were viable and fertile and no abnor-
malities were found in baseline total blood cell counts (data not
shown). Mice were bred and maintained under speciﬁc pathogen-
free conditions at the University of Dundee. All procedures were
carried out with institutional ethics approval, under home ofﬁce
license and were performed in accordance with the UK 1986 Ani-
mals (Scientiﬁc Procedures) Act. Siglec-F expression was assessed
by ﬂow cytometry of eosinophils in blood, bone marrow and lung
tissue digest from WT  and siglec-F deﬁcient mice using both a rat
anti-siglec-F mAb  (Clone E50-2440, BD Biosciences, Oxford, UK)
and a sheep anti-siglec-F pAb [8]. Eosinophils were delineated with
anti-Gr-1 antibody (RB6-8C5; eBioscience, Hatﬁeld, UK) and side-
scatter properties. Fc receptor binding was blocked with 2.4G2
(hybridoma) prior to surface staining. Following staining, cells were
ﬁxed in 1% formaldehyde. Data were collected using a LSR Fortessa
(BD Biosciences) and analyzed using Flowjo 7.5 software (Treestar).
2.2. Induction of allergic airway inﬂammation
Allergic airway inﬂammation was induced in groups of 8-week
old female siglec-F-deﬁcient mice and their WT  littermates using
two models (Fig. 2). Mice were sensitized on days 0 and 12 using
intraperitoneal OVA (Chicken egg, Grade V, Sigma, Poole, UK), at a
concentration of 50 g/mouse (model 1) in 0.2 ml  alum (Alu-Gel-S;
Serva, AMS  Biotechnology, Abingdon, UK), or 10 g/mouse in 0.2 ml
alum (model 2). To induce local inﬂammation to the airways for
model 1, mice were anaesthetized using isoﬂuorane and 20 g in
50 l OVA instilled into the nostrils on days 24, 26 and 28 [10]. For
model 2, mice were challenged daily with 5% OVA (aerosolized for
20 min) via the airways between days 21 and 23. For both models,
mice were sacriﬁced by exsanguination under terminal anesthesia
(ketamine, 100 mg/kg/xylazine, 10 mg/kg, i.p.) 24 h after the ﬁnal
OVA administration and lung tissue inﬂammation assessed.
2.3. Quantiﬁcation of lung cellular inﬂammation
Lung inﬂammation was assessed in collagenase digested lung
tissue as previously described [17]. Differential cell counts of lung
tissue digests (40× magniﬁcation; total area 0.5 mm2 per area ran-
domly selected) were performed on Diff Quik stained cytospins.
All differential counts were performed blind and in a randomized
order at the end of the study by the same observer.
2.4. Siglec-F ligand expression
Siglec-F ligand expression was assessed as described [12], with
minor modiﬁcations. 8 m sections were blocked for 1 h with 5%
normal sera from mouse and goat (Sigma) diluted in 0.5% casein
solution (Vector Labs, Peterborough, UK). 1 g/ml siglec-F-Fc (in
house) was pre-complexed to anti-human Fc Alexa-488 (Jackson
ImmunoResearch, Newmarket, UK) at a ratio of 1:1 for 1 h 4 ◦C prior
to incubation on slides for 24 h 4 ◦C. To evaluate background ﬂuo-
rescence, sections were stained with an irrelevant Fc-protein. To
evaluate sialic acid dependent binding, sections were treated with
0.17 U/mL Vibrio cholerae sialidase (Sigma) in HBSS at 37 ◦C for 1 h
prior to block. All sections were incubated with DAPI (Vector Labs)
at 0.5 g/mL in PBS for 5 min  to label nuclei and confocal images
were acquired (LSM 700 microscope and Zen 2009 software; Carl
Zeiss). Multi-channel images were created and processed in parallel
using Photoshop software (Adobe).
2.5. Data analysis
Statistics were performed using GraphPad Prism 6 software
(GraphPad Software, La Jolla, USA) and signiﬁcance between groups
was tested using a Mann Whitney U test. A p value of less than or
equal to 0.05 was considered signiﬁcant.
3. Results
3.1. Generation of siglec-F deﬁcient mice
In the course of attempting to generate siglec-FR114D ‘KI’ mice
carrying a mutation in the sialic acid binding site, we  found that
the siglec-F expression was  barely detectable on blood eosinophils
from siglec-FR114D mice by ﬂow cytometry (Fig. 1B). This was  not
due to loss of the epitope recognized by the anti-siglec-F mAb  since
similar low staining of siglec-FR114D eosinophils was observed with
an anti-siglec-F polyclonal antibody known to recognize more than
one epitope (data not shown). The greatly reduced siglec-F expres-
sion in siglec-FR114D mice was most likely due to disruption of gene
transcription arising from the targeting strategy used, since quan-
titative PCR analysis showed that siglec-F mRNA in bone marrow
from siglec-FR114D mice was decreased to ∼35% of levels found
in WT  mice (data not shown). We  also generated siglec-F−/− KO
mice by crossing siglec-FR114D mice with bal-cre mice (Fig. 1A). As
expected, lack of eosinophil siglec-F expression was  observed in the
blood (Fig. 1B), bone marrow and lung tissue digest of these mice
in comparison with WT  mice (data not shown). The percentage
of eosinophils in the blood and bone marrow of WT  and siglec-
F−/− mice were comparable at baseline (Blood: WT,  1.7% ± 0.4;
siglec-F−/−, 1.4% ± 0.2; Bone marrow: WT,  3.7% ± 0.3; siglec-F−/−,
3.6% ± 0.1).
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Fig. 1. Generation and characterization of siglec-F-deﬁcient mice. (A) Schematic representation of Siglec-F locus, the gene targeting vector to introduce R114D mutation in
exon  3 (that contains the sialic acid binding site) and the targeted allele, with the aim of generating siglec-FR114D ‘knock-in’ (KI) mice expressing full length protein that lacks
the  ability to bind sialic acid. The ‘knock-out’ (KO) allele was generated following a cross of siglec-FR114D mice with Bal1 cre mice to excise exons 6–9, in order to generate
siglec-F−/− mice (Neo, neomycin; Pur, puromycin; Tk, thymidine kinase; FRT, neomycin resistance site; F3, puromycin resistance site). (B) Flow cytometric analysis of siglec-F
on  blood eosinophils (determined by SSc/Gr1mid expression) from WT,  siglec-FR114D and siglec-F−/− mice. Top panels show representative histograms of siglec-F staining
from  unstained (gray line) and WT (dotted line) and siglec-F deﬁcient (black line) mice. Lower panels present mean ± S.D. GeoMean of siglec-F ﬂuorescence from 2 to 4 mice
per  group.
14 S.J. McMillan et al. / Immunology Letters 160 (2014) 11–16
Fig. 2. Schematic of the two models of OVA-induced airway inﬂammation tested in
siglec-F deﬁcient mice.
3.2. Investigating the functional role for siglec-F in vivo
To extend previous work using a single model of OVA-
induced airway inﬂammation [10], we compared two commonly
used models in the siglec-FR114D and siglec-F−/− mice. Models
1 and 2 differ in the concentration of OVA used for sensitiza-
tion and in the frequency and concentration of OVA challenge
to induce local inﬂammation in the lung (Fig. 2). Similar to the
total cell counts (Fig. 3), lung eosinophil numbers did not dif-
fer between WT  and siglec-F−/− mice at baseline in the absence
of OVA (means ± S.E.M., WT:  0.5 × 103 mg−1 ± 0.06; siglec-F−/−:
0.5 × 103 mg−1 ± 0.05). Using model 1, it was  previously shown that
mice deﬁcient in siglec-F had enhanced eosinophilia induced by
OVA [10]. Indeed, we conﬁrmed this phenotype in lung tissue digest
using the siglec-FR114D and siglec-F−/− mice reported here (Fig. 3).
However, using model 2, where the amount of allergen used for
sensitization is lower and the dosing of local OVA to the airways
is given daily rather than every other day, there was  no inﬂuence
of siglec-F deﬁciency on eosinophil recruitment to the lung tissue,
using either siglec-FR114D or siglec-F−/− mice (Fig. 3).
3.3. Siglec-F ligand expression in vivo
In order to determine if the difference in siglec-F-dependent
suppression of lung eosinophilia for the two models was  linked to
differential expression of siglec-F ligands, lung tissue sections from
WT mice were stained with siglec-F-Fc (Fig. 4). As reported previ-
ously [12], in untreated mice siglec-F-Fc staining was  observed both
in the apical surface of airway epithelial cells where high levels of
mucins are present, as well as in cells in the alveolar bed. This stain-
ing was  increased when mice were exposed to OVA and was also
seen on inﬂammatory cells. However, the pattern of staining and
intensity did not differ between the two  models of OVA-induced
airway inﬂammation (Fig. 4). Staining was sialic acid-dependent
and speciﬁc since sialidase treatment greatly reduced the signals
(Fig. 4) and no staining was observed using an irrelevant Fc-protein
(data not shown).
Fig. 3. Siglec-F-dependent negative regulation of allergen-induced eosinophilia depends critically on the experimental model used. WT,  siglec-FR114D and siglec-F−/− mice
were  subjected to allergic inﬂammation using either model 1 or model 2. Total and differential cells counts were enumerated in Diff Quik stained cytospins of collagenase
digests  of lung tissue (LMs; lymphomononuclear cells). Data are expressed as mean ± S.E.M., n = 4–6/group, *p ≤ 0.05 using Mann Whitney U Test.
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Fig. 4. Comparable expression of siglec-F ligands in the lung tissue of model 1 and model 2 induced allergic airway inﬂammation. The expression of siglec-F ligands in lung
tissue  taken from PBS or OVA-treated WT mice was  measured using pre-complexes of siglec-F-Fc/anti-Fc. Sections shown in lower panels were treated with sialidase prior
to  staining. Sections were analyzed by confocal microscopy (LSM 700 microscope and Zen 2009 software; Carl Zeiss) and images collected with an -Plan-Apochromat 40×
NA  1.46 objective. Scale bars represent 50 m.
4. Discussion
Using two well-characterized models of OVA-induced airway
inﬂammation that differ in the amount of OVA used for sensi-
tization and in the route/concentration of OVA delivered locally
to the lung, we demonstrate that the previously reported effect
of siglec-F on suppression of eosinophilia was only observed in
one of the models in which OVA was instilled intranasally every
other day [10]. In contrast, when OVA was aerosolised daily, the
negative regulatory effects of siglec-F were not observed. In view
of current thinking that siglec-F-dependent negative regulation of
lung eosinophilia is due to siglec-F interactions with sialylated lung
ligands triggering eosinophil cell death [18], it was  important to
compare ligand expression in both models. However, no obvious
differences were observed. These data therefore raise a number of
questions regarding the in vivo inhibitory functions of siglec-F that
seem to critically depend on subtle features of the inﬂammatory
environment.
Rather than regulating eosinophil numbers via ligand-induced
apoptosis, siglec-F may  directly suppress eosinopoiesis under the
inﬂammatory conditions of model 1. Consistent with this notion,
siglec-F-deﬁcient mice subjected to model 1 exhibited exaggerated
eosinophilia in the bone marrow and blood, as well as increased
eosinophil precursors in the bone marrow [10]. Similar to other
CD33-related siglecs, siglec-F contains ITIM-like motifs known to
recruit tyrosine phosphatases SHP-1 and SHP-2 [1]. A related ITIM-
receptor, CEACAM-1 expressed on neutrophils was  found to be a
negative regulator of granulopoiesis via SHP-1 recruitment and
inhibition of G-CSF/STAT3 signaling pathway [19]. Moreover, via
association with SHP-1, crosslinking of IRp60/CD300a inhibited the
activation of eosinophils in response to GM-CSF/IL-5 [20], so it
is plausible that siglec-F in association with SHP-1/2, mediates a
similar function in eosinopoiesis in response to IL-5 and GM-CSF
signaling in vivo [21,22] despite not being required in vitro [23].
Another possibility is that the inhibitory effect of siglec-F on
eosinophil numbers depends on the magnitude and kinetics of the
inﬂammatory response. Although eosinophil recruitment was  com-
parable between the two models, inhibitory signals from siglec-F
observed in model 1 could be masked in model 2 due to the higher
frequency of OVA challenge. Besides eosinophils, siglec-F is also
expressed on alveolar macrophages [24], and is upregulated on in
vitro activated CD4+ and CD8+ T cells [10]. It is well documented that
allergen-induced airway inﬂammation is driven by CD4+ Th2 cells
[25,26] that release cytokines such as IL-5 that promote eosinophil
proliferation and survival [27]. Therefore, siglec-F-dependent sup-
pression of Th2 cell cytokine production could also be a factor in
suppression of eosinophil numbers in model 1, but could be lost in
model 2 due to the increased frequency of antigenic stimulation.
However, in our hands, although numbers of recruited CD3+CD4+
T cells were low, we could not detect expression of siglec-F on
T cells in either model (data not shown). Expression of ITIM-
containing CD33-related siglecs in macrophages has been shown
to down-regulate cytokine production in response to inﬂamma-
tory mediators [28,29]. Hence, if model 1 (but not model 2) leads
to siglec-F-dependent suppression of alveolar macrophage-derived
factors that promote eosinophilia, this could also contribute to the
results observed in this study.
Taken together it is clear that delineating the role of siglec F in
allergen induced airway inﬂammation is complex, with the choice
of model system being crucial. Recently, models have been devel-
oped that negate the need for a peripheral sensitization step, use
environmentally and clinically relevant allergens, and replicate the
relevant features of the human disease [30,31]. Therefore, it will
be important to study siglec-F deﬁcient mice in such models to
deﬁne the functional role in vivo. Moreover, cell-type speciﬁc dele-
tion of siglec-F in eosinophils, alveolar macrophages and T cells
could help dissect the relative contribution of each cell type to
siglec-F-dependent suppression of eosinophilia.
5. Conclusion
In conclusion, we have shown that, depending on the nature
of the allergy model used, the negative regulatory role of siglec-F
on eosinophilia may  be overridden. These ﬁndings have impor-
tant implications for the translation of siglec-F in mouse models
of allergic inﬂammation to human siglec-8 in asthma and suggest
that further analysis of siglec-F mice in a number of model systems
should be evaluated.
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